Scott Woods, MD
Elizabeth Mears and House Jameson Professor of PsychiatryCards
Appointments
Psychiatry
Primary
Child Study Center
Secondary
Contact Info
About
Titles
Elizabeth Mears and House Jameson Professor of Psychiatry
Biography
Dr. Woods assesses young people at risk for psychosis through his PRIME Clinic, which also offers studies aiming to improve treatment for current symptoms and preventing progression.
Last Updated on April 07, 2025.
Appointments
Psychiatry
ProfessorPrimaryChild Study Center
ProfessorSecondary
Other Departments & Organizations
- Adult Psychiatry
- Child Study Center
- Connecticut Mental Health Center
- MR Core
- PRIME Psychosis Prodrome Research Clinic
- Psychiatry
- Yale Medicine
- Yale Ventures
Education & Training
- Resident
- Massachusetts General Hospital (1984)
- MD
- Baylor College of Medicine (1978)
Research
Overview
Predictors and Mechanisms of Conversion to Psychosis (MH082022)
Aspirin vs placebo for the psychosis prodrome
D-serine for the psychosis prodrome (MH074356)
Dutetrabenzine for tardive dyskinesia
Huperzine for cognitive enhancement in schizophrenia (MH083436)
Medical Research Interests
Adolescent Psychiatry; Prodromal Symptoms; Psychiatry; Psychotic Disorders
ORCID
0000-0002-3103-5228
Research at a Glance
Yale Co-Authors
Frequent collaborators of Scott Woods's published research.
Publications Timeline
A big-picture view of Scott Woods's research output by year.
Research Interests
Research topics Scott Woods is interested in exploring.
Tyrone Cannon
Albert Powers, MD, PhD
Philip Corlett, PhD
Godfrey Pearlson, MA, MBBS
Zailyn Tamayo
Vinod H. Srihari, MD
66Publications
279Citations
Psychotic Disorders
Prodromal Symptoms
Publications
2025
Functional Correlates of Atypical Visuoperceptual Organization in a Multisite Clinical High-Risk Sample
Pokorny V, Tran T, Williams T, Kenney J, Silverstein S, Gold J, Waltz J, Schiffman J, Ellman L, Strauss G, Walker E, Woods S, Powers A, Corlett P, Mittal V. Functional Correlates of Atypical Visuoperceptual Organization in a Multisite Clinical High-Risk Sample. Journal Of Psychopathology And Clinical Science 2025, 134: 527-539. PMID: 40193439, PMCID: PMC12162206, DOI: 10.1037/abn0000992.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsClinical high riskPsychotic-like Experiences groupClinical high-risk statusClinical high-risk samplesMeasures of cognitive abilityClinical high-risk groupHigh-risk sampleMeasuring perceptual organizationFaces taskPsychotic disordersPerceptual priorsCognitive abilitiesCognitive functionClinical groupsPerceptual organizationHealthy control groupContext-sensitiveSocial functioningTwo-tone imagesTarget circleSymbolic codeEbbinghausFunctional correlatesTaskParticipantsThe electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
Mathalon D, Nicholas S, Roach B, Billah T, Lavoie S, Whitford T, Hamilton H, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión R, Damiani S, Dzafic I, Ebdrup B, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin E, Mayol-Troncoso R, Niznikiewicz M, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf D, Rogers J, Salisbury D, Shaik R, Shankman S, Stevens M, Suen Y, Swann N, Tang X, Thompson J, Tso I, Wenzel J, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Castillo-Passi R, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Upthegrove R, Verma S, Wang J, Wolf D, Zhang T, Bouix S, Pasternak O, Cho K, Coleman M, Dwyer D, Nunez A, Tamayo Z, Wood S, Kahn R, Kane J, McGorry P, Bearden C, Nelson B, Woods S, Shenton M, Light G. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia 2025, 11: 85. PMID: 40480970, PMCID: PMC12144291, DOI: 10.1038/s41537-025-00622-0.Peer-Reviewed Original ResearchAltmetricConceptsEvent-related oscillationsEEG power spectral densityClinical outcomesMarkers of illness progressionRisks of antipsychotic drugsAuditory steady state responsePredictor of clinical outcomeMismatch negativityVariable clinical outcomesControlled clinical trialsClinical high riskTest-retest reliabilitySecondary outcome measuresEEG-based measuresVisual P300Antipsychotic drugsPaired t-testEEG protocolsClinical trialsEffective medicationsInterim analysisHigh riskPersonalized treatmentTraditional frequency bandsCHR individualsDigital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Wigman J, Ching A, Chung Y, Eichi H, Lane E, Langholm C, Vaidyam A, Byun A, Haidar A, Hartmann J, Nunez A, Dwyer D, Nasarudin A, Borders O, Scott I, Tamayo Z, Matneja P, Cho K, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Yassin W, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Wolff P, Rowland L, D’Alfonso S, Pasternak O, Bouix S, McGorry P, Kahn R, Kane J, Bearden C, Woods S, Shenton M, Nelson B, Baker J, Torous J. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 83. PMID: 40461469, PMCID: PMC12134270, DOI: 10.1038/s41537-025-00599-w.Peer-Reviewed Original ResearchAltmetricConceptsDigital componentsDigital health technologiesSmartphone-based digital phenotypingNovel digital health technologiesClinical high riskDigital phenotypingDigital dataHealth technologiesPredictive of transition to psychosisReal-life experiencesSchizophrenia ProgramDaily lifeTransition to psychosisPassive dataEpisode of psychosisPsychosis transitionMapping of experiencesTechnologyHigh riskMeta-analytic studiesCollaborative projectBody fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations
Perkins D, Jeffries C, Clark S, Upthegrove R, Wannan C, Wray N, Li Q, Do K, Walker E, Paul Amminger G, Anticevic A, Cotter D, Ellman L, Mongan D, Phassouliotis C, Barbee J, Roth S, Billah T, Corcoran C, Calkins M, Cerrato F, Khadimallah I, Klauser P, Winter-van Rossum I, Nunez A, Bleggi R, Martin A, Bouix S, Pasternak O, Shah J, Toben C, Wolf D, Kahn R, Kane J, McGorry P, Bearden C, Nelson B, Shenton M, Woods S. Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations. Schizophrenia 2025, 11: 78. PMID: 40399418, PMCID: PMC12095529, DOI: 10.1038/s41537-025-00610-4.Peer-Reviewed Original ResearchAltmetricConceptsClinical outcomesPsychosis riskChronic systemic inflammationLevels of biomarkersResults of bloodTwo-month follow-upSystemic inflammationSaliva levelsSalivary cortisol levelsFollow-upCollection of bloodBody fluid biomarkersCHR criteriaSchizophrenia ProgramPolygenic risk scoresRisk scoreMental disordersBlood proteomeSchizophreniaPreanalytical factorsBiomarkersBloodPolygenic scoresSaliva samplesCortisol levelsIncreased face perception in individuals at clinical high-risk for psychosis: mechanisms, sex differences, and clinical correlates
Tran T, Keane B, Thompson J, Robinson B, Kenney J, Williams T, Waltz J, Levin J, Kafadar E, Gold J, Schiffman J, Ellman L, Walker E, Strauss G, Mittal V, Zinbarg R, Corlett P, Powers A, Woods S, Silverstein S. Increased face perception in individuals at clinical high-risk for psychosis: mechanisms, sex differences, and clinical correlates. Schizophrenia 2025, 11: 74. PMID: 40355455, PMCID: PMC12069608, DOI: 10.1038/s41537-025-00624-y.Peer-Reviewed Original ResearchAltmetricConceptsClinical high riskCHR participantsCHR groupPhase of psychotic illnessAssessment of psychosis riskSevere positive symptomsGender of facesAssess response biasClinical correlatesPositive symptomsPsychiatric controlsPsychosis riskPsychotic illnessAccuracy of perceptionFace perceptionScrambled conditionPerceptual sensitivityPoorer roleResponse biasFace testPerceptual organizationComputerized assessmentSex differencesAltered visual perceptionPsychosisAltered brain activation during memory retrieval mediates the relationship between developmental trauma and psychotic symptom severity
Mason A, Palmer W, Cao H, Addington J, Bearden C, Cadenhead K, Cornblatt B, Perkins D, Mathalon D, Walker E, Woods S, Cannon T. Altered brain activation during memory retrieval mediates the relationship between developmental trauma and psychotic symptom severity. Schizophrenia Research 2025, 281: 115-121. PMID: 40328092, DOI: 10.1016/j.schres.2025.04.034.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsInferior parietal lobe activityPsychotic symptom severityParietal lobe activityDevelopmental traumaDelusion severityHallucination severityMemory taskNeurocognitive measuresMemory processesMemory performanceSymptom severityScale of Psychosis-risk SymptomsNorth American Prodrome Longitudinal StudyPoorer episodic memory performanceRisk of psychotic symptomsPaired-associate memory taskAssociated with memory processingMemory-associated regionsTrauma-exposed individualsEpisodic memory processesEpisodic memory tasksPsychosis-risk symptomsClinical high riskEpisodic memory performanceSubclinical delusionsTrajectories of positive symptoms and suicidality in individuals at clinical high risk for psychosis
Deng W, MacNutt C, Addington J, Bearden C, Cadenhead K, Carrión R, Keshavan M, Mathalon D, Perkins D, Stone W, Walker E, Woods S, Cannon T. Trajectories of positive symptoms and suicidality in individuals at clinical high risk for psychosis. Journal Of Affective Disorders 2025, 384: 208-213. PMID: 40334865, DOI: 10.1016/j.jad.2025.05.023.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsPositive symptomsClinical high riskSuicidal ideationCHR-PMeasures of suicidal ideationEarly stages of psychosisPersistence of suicidal ideationSeverity of depressive symptomsPositive symptom severityAssessment timepointsCHR-P participantsEmergence of suicidalityStages of psychosisCHR-P populationTargeted suicide prevention strategiesPsychotic disordersEarly psychosisSuicide prevention strategiesDepressive symptomsSymptom severityPsychosisIdeationDelusionsSuicideHallucinationsMismatch Negativity as a Predictor of Future Outcomes Among Individuals at Clinical High-Risk for Psychosis: Parsing Components of Auditory Predictive Coding in the North American Psychosis-Risk Longitudinal Study (NAPLS3) Sample
Hamilton H, Nicholas S, Hua J, Roach B, Belger A, Carrion R, Duncan E, Johannesen J, Keshavan M, Loo S, Niznikiewicz M, Light G, Billah T, Lavoie S, Whitford T, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Perkins D, Stone W, Tsuang M, Walker E, Woods S, Mathalon D, Schizophrenia A. Mismatch Negativity as a Predictor of Future Outcomes Among Individuals at Clinical High-Risk for Psychosis: Parsing Components of Auditory Predictive Coding in the North American Psychosis-Risk Longitudinal Study (NAPLS3) Sample. Biological Psychiatry 2025, 97: s69. DOI: 10.1016/j.biopsych.2025.02.180.Peer-Reviewed Original ResearchCognitive Assessment in the AMP SCZ Initiative: Harmonization Priorities and Strategies in a Diverse International Sample
Yassin W, Allott K, Bearden C, Lewandowski K, Matneja P, Zoupou E, Ruparel K, Parsa S, Ray S, Santorelli G, Wannan C, Keshavan M, Wood S, Kane J, Shenton M, Nelson B, Woods S, Gur R, Stone W, Schizophrenia A. Cognitive Assessment in the AMP SCZ Initiative: Harmonization Priorities and Strategies in a Diverse International Sample. Biological Psychiatry 2025, 97: s69-s70. DOI: 10.1016/j.biopsych.2025.02.181.Peer-Reviewed Original Research571. Preliminary Findings on the Association Between Psychotropic Medication and Symptom Profile Changes in Youth at Clinical High Risk for Psychosis
Zhou Q, Ananth A, Yuan E, Ku B, Goldsmith D, Addington J, Bearden C, Cadenhead K, Mukhtar H, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Woods S, Walker E. 571. Preliminary Findings on the Association Between Psychotropic Medication and Symptom Profile Changes in Youth at Clinical High Risk for Psychosis. Biological Psychiatry 2025, 97: s333-s334. DOI: 10.1016/j.biopsych.2025.02.810.Peer-Reviewed Original Research
Clinical Trials
Current Trials
ProNET
HIC ID2000029159RolePrincipal InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsSchizophrenia Spectrum Biomarkers Consortium (SSBC)
HIC ID2000029485RoleSub InvestigatorPrimary Completion Date12/31/2030Recruiting ParticipantsStudy of Brain Function Across the Lifespan
HIC ID2000020891RoleSub InvestigatorPrimary Completion Date07/31/2022Recruiting ParticipantsGenderBothAge18 years - 65 yearsSleep Dependent Learning in Schizophrenia and Psychosis Risk Syndrome
HIC ID1201009524RoleSub InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18 years - 55 years
News
News
Get In Touch
Contacts
Email
Academic Office Number
Appointment Number
Mailing Address
Psychiatry
300 George St
New Haven, CT 06511-
United States